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Structural Basis for Thrombin Activation
of a Protease-Activated Receptor:
Inhibition of Intramolecular Liganding
formation during embryogenesis [10] and controls the
invasion of epithelial-derived breast cancer cells [11,
12]. Given the importance of PAR1 in thrombotic and
proliferative diseases and the unique difficulty of
blocking a tethered-ligand receptor [13], considerable
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vent PAR1 from signaling to internally located G proteinsNew England Medical Center
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Thrombin [3] and other proteases such as plasmin
[19] activate PAR1 by cleaving its exodomain at the Arg
41-Ser 42 peptide bond. The new N terminus that isSummary
generated activates transmembrane signaling by a
poorly understood intramolecular liganding mechanism.Protease-activated G protein-coupled receptors
(PAR1–4) are tethered-ligand receptors that are acti- The cleaved exodomain is flexible and can reach over
and activate an adjacent receptor on the same mem-vated by proteolytic cleavage of the extracellular do-
main (exodomain) of the receptor. PAR1, the proto- brane surface [20, 21]. Synthetic peptides of five or more
amino acids can also activate PAR1 in an intermoleculartypic member of the PAR family, is the high-affinity
thrombin receptor of platelets and vascular endothe- liganding mode [22]. A number of mutagenesis studies
have been conducted [23–26] that aimed at delineatinglium and plays a critical role in blood coagulation,
thrombosis, and inflammation. Here, we describe the the inter- and intramolecular interactions between PAR1
and its peptide ligands. As with the other members ofsolution structure of the thrombin-cleaved exodomain
of PAR1. The side chains of a hydrophobic hirudin- the polypeptide-ligand class of GPCRs [27], it was antici-
pated that the ligand binding sites would include regionslike (Hir) sequence and adjacent anionic motif project
into solution. Docking of the exodomain Hir sequence in both the N-terminal exodomain (e1) and hydrophilic
extracellular loops e2–e4 (for simplicity, we have re-to exosite I of thrombin reveals that the tethered ligand
in the cleaved exodomain bends away from thrombin, ferred to extracellular loops ECL1–ECL3 as e2–e4, re-
spectively). Indeed, extracellular domain/loop swappingleaving its active site available to another large macro-
molecular substrate. The N-terminal ligand is longer experiments using human/Xenopus PAR1 chimeras [28]
and PAR1/PAR2 chimeras [29] led to the broad conclu-than anticipated and forms an intramolecular complex
with a region located in the C terminus of the exodo- sion that ligand binding determinants were potentially
present on extracellular domain e1 and loops e2–e4.main. Mutational analysis confirmed that this C-ter-
minal region is a ligand binding site for both intra- and Likewise, mutations in the e3 loop of PAR2 caused defi-
ciencies in both intra- and intermolecular liganding [30,intermolecular ligands. A lipidated-ligand binding site
peptide was found to be an effective inhibitor of throm- 31]. In other studies [24–26, 30], an emphasis was placed
on mutating extracellular anionic residues in the hopebin-induced platelet aggregation.
of identifying an appropriate partner(s) to the cationic
moieties on the ligand. Mutation of e3 residue E260 toIntroduction
Arg complemented the charge-reversed peptide ligand,
SFLLRN→SFLLEN, strongly suggesting that E260 formsThe PARs act as exquisite sensors for the presence of
extracellular proteases and help the cell respond to the a salt bridge to R46 in PAR1 [25]. Alanine substitution
of all extracellular Glu and Asp residues including E260new environment that is being altered during proteoly-
sis. The four different PARs (PAR1, PAR2, PAR3, and showed that only mutation of e3 residue D256 and e4
residue E347 significantly affected activation by intra- andPAR4) each respond to a select group of proteases
intermolecular ligands [26]. However, these mutations[1, 2]. For example, PAR1 and PAR3 are high-affinity
had little or no effect on the affinity of radioligands forreceptors for thrombin [3, 4], PAR2 is activated by tryp-
PAR1, which cast doubt upon whether these residuestase/trypsin [5], and PAR4 is activated by thrombin and
provide actual ligand binding contact(s). Moreover, thetrypsin [6]. Thrombin cleavage of PAR1 rapidly activates
recent X-ray structure of rhodopsin [32] places the D256platelet aggregation and can cause arterial thrombosis
residue in a conserved  sheet located deep within theunder high flow conditions [7, 8]. Chronic stimulation of
hydrophobic core of the extracellular loops where it isPAR1 in the prothrombotic milieu of an atherosclerotic
likely to be completely inaccessible to peptide ligand inplaque has also been implicated in smooth muscle cell
the context of PAR1. Therefore, a limitation of mutagen-proliferation and restenosis [9]. More recently, PAR1
esis is that by itself it cannot distinguish between directhas been shown to be essential for new blood vessel
versus indirect effects on ligand binding.
In addition to containing the tethered ligand, the PAR1*Correspondence: athan.kuliopulos@tufts.edu
exodomain also harbors a hirudin-like (Hir) sequence4 Present Address: Department of Science and Mathematics, Ketter-
ing University, Flint, Michigan. element [33], K51YEPF55, that is essential for high-affinity
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Figure 1. Biological Activities of the Full-Length TR78 and Thrombin-Activated TR62 Extracellular Domains of PAR1
(A) Alignment of thrombin receptor exodomains from human (h), mouse (m), hamster (c), rat (r), and Xenopus (x) with the C terminus of the
leech anticoagulant protein, hirudin. Thrombin cleaves the TR78 exodomain after R41 to generate TR62 (S42-hSer103). Plasmin cleaves the
exodomains at the P1–P3 sites located in the flexible linker that separates the ligand from the ligand binding site-1. TM1 indicates the predicted
start of the first transmembrane  helix.
(B) Activation of human platelets by thrombin, TR62, and SFLLR. The data were fit to a one-site equation y  (m1  m2/(1  ([agonist]/
EC50n))  m2) by nonlinear regression analysis using Kaleidagraph 3.05, where n is the hill coefficient and m1 and m2 are the minimum and
maximum asymptotes, respectively.
(C) TR78 (M concentrations indicated on each trace) inhibits 3 nM thrombin-dependent Ca2 fluxes in human platelets. Intracellular Ca2
fluxes were monitored as the ratio of fluorescence excitation intensities at 340/380 nm as described in Experimental Proceduers.
interactions with thrombin [34–36]. X-ray crystallo- sterically enhanced by the presence of the docked Hir
sequence. Following cleavage, thrombin remains asso-graphic analyses of thrombin complexed with short
PAR1 exodomain peptides comprising Leu 38 to Ser 64 ciated with the C-terminal portion of the PAR1 exodo-
main via this high-affinity Hir sequence [38]. Comple-showed that the Hir sequence of PAR1 bound to exosite
I of thrombin [37]. However, under the conditions of mentary studies with an array of thrombin active site and
exosite mutants further demonstrated the importance ofcrystallization, the PAR1 peptides adopted an unusual
antiparallel  sheet structure sandwiched between two the thrombin exosite I for efficient binding and cleavage
of PAR1 peptides [39].thrombin molecules. In this structure, the Hir sequence
docked in the expected manner at exosite I of one throm- Here, we determine the NMR structure of the throm-
bin-cleaved PAR1 exodomain. Docking of the PAR1 exo-bin molecule, but the PAR1 cleavage sequence bound in
a nonproductive mode with the active site of an adjacent domain Hir motif to exosite I of thrombin reveals that
the active site of thrombin is readily accessible to an-thrombin molecule. The physiological significance for
this unexpected thrombin:PAR1:thrombin binding mode other large macromolecular substrate. This supports the
notion that an additional role of the PAR1 Hir sequenceremains to be identified.
Steady-state kinetic studies using soluble full-length is to tether thrombin to the platelet surface and assist
in the cleavage of other nearby platelet receptors thatPAR1 exodomains showed that the initial binding of the
Hir sequence of PAR1 with exosite I is essential for lack a high-affinity Hir-like sequence. The N-terminal
tethered ligand forms an intramolecular complex with arapid association to thrombin [38]. In a second and rate-
limiting step, the exosite I-bound Hir motif facilitates the region located in the C terminus of the PAR1 exodomain
that was confirmed to be an authentic ligand bindingproductive interaction of the PAR1 cleavage sequence
to the active site of thrombin. The subsequent irrevers- site in full-length receptor. Thus, a lipidated ligand bind-
ing site peptide, P85AFISEDASGYL96C-(p-maleimidophe-ible steps of peptide bond cleavage are rapid and allo-
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Figure 2. Solution Structure of the Thrombin-
Activated PAR1 Exodomain, TR62, Residues
42–103
The rmsd for the mean coordinate positions
was 1.9 0.4 A˚ for residues 43–51 and 85–89
and 2.3  0.4 A˚ for residues 52–56 and 62–69
for the backbone atoms (N, C, C) of an en-
semble of the best ten structures (see Sup-
plemental Table S1 at Chemistry & Biology’s
website). No distance restraint was violated
by more than 0.2 A˚, and no torsional restraint
was violated by more than 5	. The total energy
was 251  31 kcal mol1, and the van der
Waals energy was 319  16 kcal mol1.
P1–P3 indicate the three plasmin cleavage
sites located on the flexible linker separating
the anionic WEDEE motif from ligand binding
site-1.
nyl-butyramide)-phosphoethanolamine(dipalmitoyl), The most striking structural feature is that the N-ter-
minal S42FLLRNPNDK51 tethered ligand docks onto thecould completely block aggregation of human platelets
surface of C-terminal residues P85AFIS89, a region whichinduced by thrombin.
we have termed ligand binding site-1 (LBS-1). Mutagen-
esis studies previously identified a similar region as an
Results and Discussion essential receptor-activation motif [24]. As shown in Fig-
ure 2, the aromatic ring of ligand residue Phe 43 comes
Structure of the Thrombin-Cleaved into van der Waals contact with the side chain of Ser
PAR1 Exodomain 89 which projects from the end of LBS-1. Eight NOEs
Previous studies demonstrated that the N-terminal exo- were observed between Phe 43 and Ser 89, demonstra-
domain of PAR1 (Figure 1A) contains all of the determi- ting an extensive intramolecular interaction. Because of
nants for thrombin recognition and cleavage [36]. In E. the relatively dynamic nature of the structure, we cannot
coli [19], we produced a soluble version of the PAR1 determine the occupancy of any particular NOE interac-
exodomain, residues A26-homoSer103 (TR78), which has tion and cannot rule out an NOE being transient. How-
high affinity (Kis  2.4 M) for thrombin [38]. Cleavage ever, mutation of Phe 43 to Ala abrogates intramolecular
with 10 nM thrombin yielded the C-terminal fragment, receptor activation [20], and the S89A mutant displays
residues S42-hS103 (TR62). The TR62 exodomain is able a 23- to 60-fold loss in activity to small peptide agonists
to fully activate human platelets with EC50 of 40 M, [25, 26]. The adjacent LBS-1 Ile 88 residue forms hy-
similar to activation of PAR1 with SFLLR, a peptide de- drophobic contacts with ligand residue Leu 44, and mu-
rived from the N terminus of TR62 (Figure 1B). The full- tation of Ile 88 to Ala causes a 40- to 60-fold loss in
length exodomain, TR78, does not activate platelets peptide agonist activity [25, 26]. The aromatic ring of
(Figure 1B) but is able to inhibit thrombin-dependent Phe 87 and the anionic residues at the C-terminal side
Ca2 fluxes with IC50 of 50 M (Figure 1C), most likely of LBS-1, Glu 90, and Asp 91 do not come into contact
because it can directly compete for platelet PAR1 as a with the ligand; accordingly, mutation of these residues
thrombin substrate [19]. to Ala had little or no effect on receptor activation [24–
The thrombin-cleaved exodomain, TR62, exhibited 26]. Likewise, the N-terminal -amino group of Ser 42
much higher solubility than TR78 for the extended times does not come into contact with LBS-1. A free N-ter-
required for NMR data acquisition while retaining biolog- minal amino group is not strictly necessary for agonist
ical activity; therefore, we chose TR62 for structural de- activity and is absent in the antagonist, BMS-200661
termination. As a reflection of its biological function, the (Kd  20 nM) [15], which has a bulky N-trans-cinnamoyl
TR62 exodomain was flexible but had obvious tertiary group in place of the N-terminal serine. However, substi-
structure because of the observations of nuclear Over- tutions of the aryl moiety of the cinnamoyl group indi-
hauser effect (NOE) crosspeaks between Trp 56 and cated a high degree of structural specificity. Therefore,
methyl resonances from aliphatic residues distant in the it is likely that the extreme N terminus of the ligand fits
sequence. The N- and C-terminal regions of the TR62 into a binding pocket defined by other e2–e4 residues
exodomain are the most structured and are separated which can accommodate both the cationic N-terminal
by a flexible linker comprising residues Arg 70 to Lys Ser 42 and the larger, neutral, cinnamoyl group of BMS-
200661.82 (Figure 2).
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An unexpected interaction was found between Pro Intra- and Intermolecular Liganding
To help identify conformational changes that may take85-Ala 86 and the peptide backbone of Asp 50-Lys 51
(Figure 2), revealing that the intramolecular ligand is place following exodomain cleavage by thrombin, we
compared the chemical shift patterns of the peptideconsiderably longer than was predicted by structure-
function studies [22, 40]. It is also noteworthy that the backbone 1H-15N HSQC crosspeaks arising from TR62
with those of the uncleaved exodomain, TR78 (Figureligand forms a tight turn about Arg 46 whose guanidino
group projects away from LBS-1. Interestingly, cyclic 3A). The HSQC spectra of the two exodomains are highly
superimposable, with the important exception of thepeptide ligands such as cyclo(Phe-Leu-Leu-Arg-
Lys)
which are bent at the analogous Arg 46 position are tethered ligand region, which indicates that the overall
structures of the cleaved and uncleaved exodomainspotent agonists of PAR1 [41]. Therefore, it is possible
that a bent conformation may also occur with linear are quite similar. The 1H-15N crosspeaks from ligand resi-
dues Leu 44, Leu 45, Arg 46, and Asn 47 gave shiftsintermolecular agonists such as SFLLRN. In addition,
mutation of Arg 46 to Ala causes a 33-fold loss in activity much larger than that expected from simply breaking
the Arg 41-Ser 42 peptide bond [43], indicating that thein the context of small peptide agonists [22], and the
guanidino group is an important phamacophore for structure of the ligand region in the thrombin-cleaved
exodomain is quite different from that of uncleaved exo-small molecule anti-PAR1 compounds [15]. Thus, it is
likely that yet another region or regions [25] of the extra- domain. Smaller shifts were seen in the HSQC cross-
peaks arising from Hir residues Tyr 52, Glu 53, and Phecellular loops (e2–e4) of PAR1 will provide further ligand
binding surfaces for this cationic moiety, potentially as 55 of TR62 versus TR78. Therefore, the Hir region may
slightly change its conformation following thrombina second event in a two-step liganding process. In a
potentially analogous mechanism, the glycoprotein hor- cleavage [38] and intramolecular liganding. The cross-
peaks arising from LBS-1 residues were superimpos-mone GPCRs are activated in two steps whereby the
glycoprotein ligand (LH, FSH, CG, TSH) first binds with able in TR62 and TR78. In addition, no NOE interactions
were detected between the ligand region and LBS-1 inhigh affinity to the N-terminal e1 domain of the receptor
and then makes secondary contacts with the other ex- TR78 (data not shown). This indicates that the Ala 26-
Arg 41 N-terminal extension present in the uncleavedtracellular loops to generate a signal [27].
The NMR structure of the PAR1 exodomain also exodomain may disrupt intramolecular liganding by
changing the structure of the tethered ligand rather thanshows that the thrombin-interacting Hir sequence,
Y52EPF55, extends directly away from the ligand region the ligand binding site. Note that differences in chemical
shifts illustrate a change in environment, such as one(Figure 2). Loss of this Hir motif causes a 73-fold reduc-
tion in the association rate of thrombin to the exodomain caused by a conformational change, but a structural
difference can only be confirmed by solving the struc-[38], and individual mutation of Tyr 52, Glu 53, or Phe
55 to Ala causes up to a 50-fold loss in the ability of ture of the larger TR78.
The intramolecular liganding between the N-terminalthrombin to activate full-length receptor [35]. The aro-
matic side chains of Tyr 52 and Phe 55, along with Glu residues of TR62 and the LBS-1 region was further dem-
onstrated by competition titration NMR studies of TR6253, project into solution where they are easily accessible
for forming interactions with exosite I of thrombin (see with free peptide ligand. As shown in Figure 3B, addition
of SFLLRN caused selective shifts in the 1H-15N cross-Figure 5). Adjacent to the Hir motif is an anionic E57DEE60
cluster that splays outward from the exodomain where peaks of ligand residues Leu 44, Leu 45, and Arg 46 in
TR62. Nearly identical results were seen with the high-it is available for electrostatic interactions with the posi-
tively charged thrombin exosite-1 [33]. A hydrophobic affinity BMS-200661 PAR1-antagonist (data not shown).
This provides the first direct evidence that small peptidescaffolding residue, Trp 56, anchors both the adjacent
Hir and EEDE motifs by making numerous contacts (n ligands and antagonists can displace the tethered ligand
from LBS-1 in the TR62 exodomain, as occurs with the28 NOEs) with Pro 54, Phe 55, Glu 57, Asp 58, Leu 66, and
Thr 67. Kinetic analyses of soluble PAR1 exodomains thrombin-cleaved receptor on intact cells [16, 44]. As
expected, addition of SFLLRN (Figure 3C) or BMS-showed that the presence of Trp 56 enhances the affinity
of the adjacent Hir sequence for exosite I of thrombin 200661 (data not shown) to TR78 caused no movement
of the 1H-15N crosspeaks of the preligand region, provid-by 11-fold [42]. The R70-K82 linker region joining the EDEE
motif to LBS-1 is likely to be the most dynamic portion ing further evidence that the preligand does not form
an intramolecular complex with the ligand binding siteof TR62, as indicated by the relatively low number of
NOE interactions within this segment and the absence in the uncleaved PAR1 exodomain.
To further test the validity of the structure of the solu-of NOEs to other parts of the protein (see Supplemental
Figure S1 at http://www.chembiol.com/cgi/content/full/ ble exodomain as a model for full-length receptor, we
deleted the P85AFIS89 region, expressed the P85AFIS8910/11/1033/DC1). This is the region that is efficiently
cleaved by plasmin [19] at the P1-P3 sites (Figures 1A mutant receptor in COS7 fibroblasts, and measured
PAR1-dependent stimulation of PLC-. As shown in Fig-and 2). We postulate that this linker serves dual pur-
poses: (1) it provides sufficient conformational flexibility ure 4A, the EC50 for SFLLRN stimulation of PLC- shifted
13,000-fold for PAFIS relative to wild-type receptor.for the exodomain N-terminal ligand to achieve the cor-
rect geometry necessary to reach the ligand binding The P85AFIS89 mutation also caused a 73-fold shift in
EC50 for thrombin and reduced efficacy by 2.5-fold. It issite, and (2) its flexibility allows for truncation by serum
proteases such as plasmin by a negative feedback unlikely that this right shift in EC50 is due to a lower
affinity for thrombin, because previous studies showedmechanism during the anticoagulation phase of hemo-
stasis [19]. that deletion of the C terminus of the exodomain includ-
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Figure 3. Movement of the Ligand Region of the PAR1 Exodomain Following Thrombin Cleavage or upon Displacement by the Small Peptide
Ligand, SFLLRN
(A) Superposition of 1H/15N HSQC spectra of full-length TR78 (1.4 mM) and thrombin-cleaved TR62 (1.6 mM) in 20 mM sodium phosphate (pH
7.2), 5% D2O, 5	C. Selected 1H/15N crosspeaks are labeled in blue (ligand), purple (Hir), red (WEDEE), and yellow (ligand binding site-1).
(B) Overlay of 1H/15N HSQC spectra of TR62 (1.6 mM) and TR62 (0.93 mM) in the presence of SFLLRN ligand (2.76 mM). Boxed crosspeaks
highlight the only differences in the two spectra occurring in the ligand region of TR62.
(C) Overlay of 1H/15N HSQC spectra of TR78 (0.88 mM) and TR78 (0.8 mM) in the presence of SFLLRN ligand (2.4 mM).
ing the LBS-1 region [38] produced a 2-fold higher affin- mimic the extracellular loops of the intact receptor and
may either bind to the ligand or indirectly perturb theity for thrombin compared to the full-length exodomain.
Likewise, deleterious mutations in intracellular loops ligand binding pocket. Therefore, using the structure of
the cleaved exodomain as a starting point, we testedcan cause right shifts in the EC50 for the thrombin-gener-
ated tethered ligand [17]. Therefore, the most likely ex- whether a peptide fragment comprising LBS-1 residues
P85-L96C could inhibit intramolecular liganding of PAR1planation for the right shift in thrombin EC50 by the LBS-1
mutant is that a greater fraction of receptors needs to on human platelets. The LBS-1 peptide did inhibit plate-
let Ca2 fluxes generated by 3 nM thrombin (Figure 4B)be cleaved in order to generate a signal. The severe
defects in receptor activation strongly support the NMR or by 3 M SFLLRN (data not shown). However, the IC50
(120 M) was relatively weak, and concentrations ofdata that the P85AFIS89 LBS-1 region is a major binding
site for both intra- and intermolecular ligands. The resid- LBS-1 peptide up to 120 M did not inhibit thrombin-
induced platelet aggregation (Figure 4C). Other exodo-ual activity of the P85AFIS89 mutant at saturating con-
centrations of thrombin and SFLLRN is likely due to main peptides, A26-R41 and T67-L84 (1–300 M), did not
inhibit thrombin or SFLLRN activation of PAR1 (data notthe presence of other ligand binding regions from the
extracellular loops e2–e4, as previously described for shown). To enhance effective molarity at the platelet
surface and reduce degrees of freedom, we attachedPAR1 [25, 26] and PAR2 [31].
a lipid moiety (dipalmitoyl-phosphoethanolamine) to a
C-terminal cysteine, a position on the LBS-1 peptideLigand Binding Site-1 Peptide Antagonists
Previous studies [45] demonstrated that soluble extra- that was predicted to come into close proximity with
the lipid bilayer in the intact receptor (see Figure 5). Incellular loop fragments of the V1a vasopressin receptor
are low micromolar inhibitors of vasopressin binding. marked contrast to the soluble LBS-1 peptide, the C
terminally lipidated peptide, LBS1-PE, was a highly ef-These studies suggested that the peptides (13–25-mers)
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Figure 4. The P85AFIS89 Region of PAR1 Is a
Ligand Binding Site for Both the Tethered and
Free Peptide Ligand, SFLLRN
(A) Effect of deletion of P85AFIS89 on the ability
of PAR1 to signal to PLC- in fibroblasts.
COS7 cells were transiently transfected with
pDEF3 vector encoding wild-type PAR1 (brown
circles), P85AFIS89 PAR1 (blue squares), or
empty vector (green diamonds) and chal-
lenged with 1 pM to 1 M thrombin (open
symbols) or 1 nM to 1 mM SFLLRN peptide
(closed symbols). The P85AFIS89 mutant was
expressed equally as well as wild-type PAR1
as assessed by flow cytometry with the anti-
SFLLR Ab [19]. PLC- activity was deter-
mined by measuring total [3H]inositol phos-
phate (InsP) formation, and the data were fit
as in Figure 1B.
(B) The LBS-1 peptide (P85AFISEDASGYL96-C)
spanning the ligand binding site-1 region
(Figure 1A) inhibits thrombin activation of hu-
man platelets. Gel-filtered platelets were pre-
incubated with the indicated concentrations
of LBS-1 peptide (110–540M) and then chal-
lenged with 3 nM thrombin. Intracellular Ca2
fluxes were measured as in Figure 1C. The
LBS-1 peptide was not a direct thrombin in-
hibitor at concentrations up to 300 M as
assessed by competition studies with small
chromogenic substrates [38].
(C) Effect of C-terminal lipidation of the LBS-1
peptide with dipalmitoyl-phosphoethanola-
mine (LBS1-PE) on antagonism of thrombin-
induced platelet aggregation. Gel-filtered hu-
man platelets were pretreated for 5 min with
either soluble LBS-1 or LBS1-PE, and aggre-
gation was induced with 5 nM thrombin.
fective inhibitor of platelet aggregation. As shown in based structure of TR62 onto the surface of thrombin
by superimposing the side chains of the three critical HirFigure 4C, 23 M LBS1-PE completely inhibited 5 nM
thrombin-induced platelet aggregation. Similarly lipi- residues, Tyr 52, Glu 53, and Phe 55, with the analogous
residues of hirulog-3 bound to thrombin [47]. Notably,dated extracellular loop peptides such as KEQTIQVP
GLNITTC(dipalmitoyl-phosphoethanolamine)HDVL the model of the TR62-thrombin complex (Figure 5)
shows that the N-terminal ligand bends away from theNETLLEGY had no effect on platelet aggregation at con-
centrations up to 50 M (data not shown). Therefore, surface of thrombin in order to form the intramolecular
contacts with the LBS-1 region of the PAR1 exodomain.anchoring a ligand binding site peptide to the cell sur-
face with a lipid moiety at the appropriate position may This is consistent with the conformational change in
the ligand region following cleavage of the full-lengthinterfere with agonist binding either by directly inter-
acting with the ligand or by binding to the receptor itself exodomain by thrombin (Figure 3A). This more open
geometry is in marked contrast to the three-stranded and altering the ligand binding pocket [45].
sheet PAR1 structure observed in the thrombin-
PAR1(L38-E60)-thrombin cocrystal [37]. The PAR1 exodo-Docking of Thrombin to the PAR1 Exodomain
An interesting feature of thrombin-PAR interactions on main-thrombin model in Figure 5 leaves the active site
of thrombin free to simultaneously interact with otherplatelets is that near-stoichiometric amounts of throm-
bin, rather than catalytic amounts, are required for plate- large macromolecules, such as the lower affinity PAR4
receptor, which lacks a Hir-like sequence [42]. This ac-let activation [46]. This raises the possibility that the low
turnover of thrombin could be due to tight binding and cessible active site is interesting in light of recent studies
that have shown that mouse PAR3 serves as a Hir-a relatively slow off-rate from cleaved receptors. Indeed,
previous kinetic studies [38] demonstrated that the Hir containing thrombin binding site that assists in the
cleavage of adjacent PAR4 receptors [48]. Although theregion of TR62 confers high-affinity binding (Ki  9.4
M) of thrombin-cleaved exodomain to thrombin. To analogous cofactoring between PAR1 and PAR4 has yet
to be shown, our model provides a mechanistic basisprovide a model of this complex, we docked the NMR-
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terminus of the exodomain. The ligand region is longer
than anticipated and includes peptide backbone con-
tacts between Asp 50-Lys 51 and Pro 85-Ala 86. Unlike
a soluble LBS-1 peptide, a lipidated LBS-1 peptide,
P85AFISEDASGYL96C-(p-maleimidophenyl-butyramide)-
phosphoethanolamine(dipalmitoyl), could completely
block aggregation of human platelets induced by 5
nM thrombin. Thus, anchoring a ligand binding site
peptide to the cell surface with a lipid moiety at the
appropriate position may either create a competing
binding site for the ligand or perturb the ligand binding
pocket of the intact receptor and block receptor acti-
vation.
Experimental Procedures
NMR Sample Preparation
Full-length PAR1 exodomain, TR78, was expressed from Esche-
richia coli as a KSI-M-TR78-M-His6 fusion protein and purified by
Ni chelate chromatography using the pET31 vector [49]. TR78 was
cleaved at interspersed methionines from KSI carrier protein and
His6 tag using CNBr/70% formic acid and purified by RP-HPLC as
described [19]. TR62 was made by incubating 200–400 M TR78
with 10 nM thrombin at 25	C for 1 hr. The C-terminal exodomain,
TR62, was purified from the N-terminal TR16 cleavage fragment
(A26-R41) by RP-HPLC and reconstituted in 20 mM NaHPO4, 150 mM
NaCl (PBS) (pH 7.2). Uniformly 15N-labeled protein was preparedFigure 5. Model of the PAR1 Exodomain, TR62, Complexed with
by growing cells in M9 medium supplemented with 15NH4Cl. NMRThrombin
samples contained 0.6–1.6 mM exodomain.The amino acid residues on thrombin are colored as follows: red,
Ser 195; green, Lys 36, Arg 67, Arg 75, Arg 77a, Lys 81, Lys 109,
NMR Structure DeterminationLys 110; and yellow, Leu 40, Leu 65, Tyr 76, Ile 82.
NMR spectra were collected at 5	C on a Bruker 500 MHz spectrome-
ter. 1H and 15N resonances were assigned from two- and three-
dimensional TOCSY and TOCSY-HSQC experiments. Distance re-
for cofactoring that might occur between high-affinity straints were obtained from two-and three- dimensional NOESY and
(PAR1, PAR3) and low-affinity (PAR4) thrombin recep- NOESY-HSQC experiments, and φ-angle restraints were based on
the 3JHNH coupling constants. Structures of TR62 were calculatedtors [48].
with a square-well potential and force constant of 50 kcal1 mol1 A˚2
by distance geometry/simulated annealing algorithms using the
Significance X-PLOR program [50].
Molecular ModelingThe protease-activated receptors, PAR1, PAR2, and
The NMR-derived structure of TR62 was docked onto the surfacePAR4, play a major role in blood coagulation and in
of thrombin using the X-ray structural coordinates of the thrombin-mediating the cellular responses to injury and inflam-
hirulog-3 complex [47] as a model. Energy minimization was per-mation in many tissues. More recently, PAR1 has been
formed to eliminate van der Waals violations and resulted in a rmsd
shown to be an oncogene that controls the invasion of 0.8 A˚ between the atomic coordinates of thrombin complexed
and metastasis of cancer cells. There has been a con- with hirulog-3 versus thrombin complexed with TR62 and a rmsd
of 1.4 A˚ between the original atomic coordinates of uncomplexedcerted effort by the pharmaceutical industry to devel-
TR62 and docked TR62. Energy minimization did not alter any signifi-op anti-PAR drugs; however, these efforts have been
cant structural features, with the major movement in the peptidelargely thwarted due to the difficulty of antagonizing
backbone of TR62 occurring in the flexible linker residues R70-K82.receptors that form intramolecular complexes with
their own ligand. Here, we determine the structural Synthesis of LBS1-PE
basis for proteolytic activation of the prototypic PAR1 The LBS-1 peptide included a C-terminal cysteine residue
(P85AFISEDASGYL96-C) and was synthesized by solid-phase fmocthrombin receptor and lay the foundation toward the
chemistry. Lipidation of the C-terminal cysteine thiol of LBS-1 wasdevelopment of more effective anti-PAR small mole-
done with N-MPB-PE (1,2-dipalmitoyl-sn-glycero-3-phosphoeth-cules. NMR experiments indicate that following cleav-
anolamine-N-[4-(p-maleimidophenyl)-butyramide]) by mixing 2.5 mMage by thrombin the PAR1 exodomain undergoes a
peptide and 5 mM N-MPB-PE (Avanti Polar Lipids) in 6% triethyla-
major conformational change in the ligand region and mine/17% H2O/77% dimethylformamide and incubating at 23	C for
a smaller conformational change in the thrombin exo- 2 hr. The LBS-1 peptide-Cys-PE conjugate was purified by Sep-
Pak (Waters) C18 reverse-phase chromatography, and identity wassite I binding Hir residues. Docking of the exodomain
confirmed by mass spectrometry.Hir sequence to exosite I of thrombin revealed that
the tethered ligand in the cleaved exodomain bends
Inositol Phosphate Assayaway from thrombin, leaving the thrombin active site
Accumulation of [3H]inositol phosphates was measured in the pres-
available to another large macromolecular substrate. ence of 20 mM LiCl. COS7 cells were split into 12-well plates at
The N-terminal ligand forms an intramolecular com- 200,000 cells/well. [3H]-labeled myoinositol (2 Ci/ml) was added to
cells 24 hr prior to the experiment. Wells were rinsed twice with 2plex with the LBS-1 region (P85AFIS89) located in the C
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ml DME containing 10 mM HEPES buffer (pH 7.3), then rinsed twice attenuates vascular restenosis following balloon angioplasty in
rats. J. Pharmacol. Exp. Ther. 298, 34–42.with 2 ml PBS containing 20 mM LiCl. Cells were stimulated with
agonist for 30 min and then extracted with cold methanol and chloro- 8. Bahou, W.H. (2002). Attacked from within, blood thins. Nat. Med.
8, 1082–1083.form. Extracts were loaded onto columns containing 1 ml anion-
exchange resin AG1X8, formate form, 100–200 mesh size (Bio-Rad 9. Nelken, N.A., Soifer, S.J., O’Keefe, J., Vu, T.-K.H., Charo, I.F.,
and Coughlin, S.R. (1992). Thrombin expression in normal andLaboratories, Cambridge, MA). After loading, columns were washed
twice with 10 ml H2O and twice with 10 ml 60 mM ammonium for- atherosclerotic human arteries. J. Clin. Invest. 90, 1614–1621.
10. Griffin, C.T., Srinivasan, Y., Zheng, Y.-W., Huang, W., andmate/5 mM Borax. Column fractions were eluted with 4 ml 2 M
ammonium formate/0.1 M formic acid into vials containing 7.5 ml Coughlin, S.R. (2001). A role for thrombin receptor signaling in
endothelial cells during embryonic development. Science 293,scintillation cocktail and counted. The mean of triplicate determina-
tions was expressed as fold-stimulation above nonstimulated cells. 1666–1670.
11. Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S.,
Maoz, M., Ginzburg, Y., Reich, R., Vlodavsky, I., and Bar-Shavit,Platelet Aggregation and Ca2 Flux Measurements
R. (1998). Thrombin receptor overexpression in malignant andHuman platelets were obtained from adult volunteers using informed
physiological invasion processes. Nat. Med. 4, 909–914.consent procedures approved by the Tufts-NEMC Institutional Re-
12. Kamath, L., Meydani, A., Foss, F., and Kuliopulos, A. (2001).view Board. Blood was collected into a 30 ml syringe containing
Signaling from protease-activated receptor-1 inhibits migration10% Na citrate as anticoagulant using an 18G needle. Platelets were
and invasion of breast cancer cells. Cancer Res. 61, 5933–5940.purified by gel filtration, and activation was measured by
13. Hollenberg, M.D. (2000). Receptor binding and agonist efficacy:14C-serotonin release [51] following challenge with agonist. For Ca2
new insights from mutants of the thrombin protease-activatedsignaling assays, platelets were labeled with 2.5 M Fura 2-AM
receptor-1 (PAR1). Mol. Pharmacol. 58, 1175–1177.(Molecular Probes) for 30 min at 37	C. Platelets were then washed
14. Cook, J.J., Sitko, G.R., Bednar, B., Condra, C., Mellot, M.J.,and resuspended with an equal volume of modified PIPES buffer.
Feng, D.-M., Nutt, R.F., Shafer, J.A., Gould, R.J., and Connolly,Ca2/Fura-2 fluorescence was measured as previously [46] using a
T.M. (1995). An antibody against the exosite of the cloned throm-Perkin Elmer LS50B fluorescence spectrophotometer. For platelet
bin receptor inhibits experimental arterial thrombosis in the Afri-aggregation measurements, isolated platelets were counted on a
can green monkey. Circulation 91, 2961–2971.Coulter counter, and the concentration was adjusted to 1.5  108/
15. Bernatowicz, M.S., Klimas, C.E., Hartl, K.S., Peluso, M., Alle-ml with modified PIPES buffer. Platelet aggregation was measured
gretto, N.J., and Seiler, S.M. (1996). Development of potentby light scattering of stirred platelets (900 rpm) at 37	C on a Chrono-
thrombin receptor antagonist peptides. J. Med. Chem. 39, 4879–log 560VS/490-2D aggregometer using modified PIPES buffer as a
4887.blank. Platelet samples (250 l) were preincubated at 37	C with 1.5
16. Andrade-Gordon, P., Maryanoff, B.E., Derian, C.K., Zhang,mM CaCl2 and treated with LBS-1 or LBS1-PE (dissolved in 50%
H.-C., Addo, M.F., Darrow, A.L., Eckardt, A.J., Hoekstra, W.J.,DMF/50% DMSO) for 5 min before the addition of human -thrombin
McComsey, D.F., Oksenberg, D., et al. (1999). Design, synthesis,(Haematologic Technologies Inc., Essex Junction, VT). Percent ag-
and biological characterization of a peptide-mimetic antagonistgregation was determined from the extent of aggregation at 5 min.
for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA 96,
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